JP2019533807A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019533807A5 JP2019533807A5 JP2019515904A JP2019515904A JP2019533807A5 JP 2019533807 A5 JP2019533807 A5 JP 2019533807A5 JP 2019515904 A JP2019515904 A JP 2019515904A JP 2019515904 A JP2019515904 A JP 2019515904A JP 2019533807 A5 JP2019533807 A5 JP 2019533807A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antigen
- binding fragment
- muc16
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662399249P | 2016-09-23 | 2016-09-23 | |
| US62/399,249 | 2016-09-23 | ||
| US201762558711P | 2017-09-14 | 2017-09-14 | |
| US62/558,711 | 2017-09-14 | ||
| PCT/US2017/053114 WO2018058003A1 (en) | 2016-09-23 | 2017-09-22 | Anti-muc16 (mucin 16) antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019533807A JP2019533807A (ja) | 2019-11-21 |
| JP2019533807A5 true JP2019533807A5 (https=) | 2020-10-22 |
| JP7066690B2 JP7066690B2 (ja) | 2022-05-13 |
Family
ID=60083442
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019515905A Active JP7066691B2 (ja) | 2016-09-23 | 2017-09-22 | 二重特異性抗ｍｕｃ１６－ｃｄ３抗体および抗ｍｕｃ１６薬物複合体 |
| JP2019515904A Active JP7066690B2 (ja) | 2016-09-23 | 2017-09-22 | 抗ｍｕｃ１６（ムチン１６）抗体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019515905A Active JP7066691B2 (ja) | 2016-09-23 | 2017-09-22 | 二重特異性抗ｍｕｃ１６－ｃｄ３抗体および抗ｍｕｃ１６薬物複合体 |
Country Status (29)
| Country | Link |
|---|---|
| US (4) | US10738130B2 (https=) |
| EP (3) | EP4273172A3 (https=) |
| JP (2) | JP7066691B2 (https=) |
| KR (2) | KR102418667B1 (https=) |
| CN (2) | CN110214026B (https=) |
| AU (2) | AU2017339711B2 (https=) |
| BR (2) | BR112019005670A2 (https=) |
| CA (3) | CA3037536C (https=) |
| CL (4) | CL2019000712A1 (https=) |
| CO (1) | CO2019003967A2 (https=) |
| CY (1) | CY1125577T1 (https=) |
| DK (2) | DK3515946T5 (https=) |
| ES (2) | ES2952735T3 (https=) |
| FI (1) | FI3515487T3 (https=) |
| HR (2) | HRP20221202T1 (https=) |
| HU (2) | HUE063020T2 (https=) |
| IL (2) | IL265369B2 (https=) |
| LT (2) | LT3515487T (https=) |
| MD (1) | MD3515487T2 (https=) |
| MX (2) | MX2019003322A (https=) |
| MY (2) | MY194596A (https=) |
| PH (2) | PH12019500550A1 (https=) |
| PL (2) | PL3515487T3 (https=) |
| PT (2) | PT3515487T (https=) |
| RS (2) | RS63660B1 (https=) |
| SI (2) | SI3515946T1 (https=) |
| SM (2) | SMT202200359T1 (https=) |
| WO (2) | WO2018067331A1 (https=) |
| ZA (2) | ZA201901557B (https=) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI682941B (zh) | 2013-02-01 | 2020-01-21 | 美商再生元醫藥公司 | 含嵌合恆定區之抗體 |
| CA2981312C (en) | 2015-03-30 | 2023-09-26 | Regeneron Pharmaceuticals, Inc. | Heavy chain constant regions with reduced binding to fc gamma receptors |
| TWI829617B (zh) | 2015-07-31 | 2024-01-21 | 德商安美基研究（慕尼黑）公司 | Ｆｌｔ３及ｃｄ３抗體構築體 |
| TWI796283B (zh) | 2015-07-31 | 2023-03-21 | 德商安美基研究（慕尼黑）公司 | Ｍｓｌｎ及ｃｄ３抗體構築體 |
| TWI744242B (zh) | 2015-07-31 | 2021-11-01 | 德商安美基研究（慕尼黑）公司 | Egfrviii及cd3抗體構築體 |
| EA039859B1 (ru) | 2015-07-31 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Биспецифические конструкты антител, связывающие egfrviii и cd3 |
| LT3353212T (lt) * | 2015-09-23 | 2021-12-27 | Regeneron Pharmaceuticals, Inc. | Optimizuoti anti-cd3 bispecifiniai antikūnai ir jų naudojimas |
| US11583593B2 (en) | 2016-01-14 | 2023-02-21 | Synthis Therapeutics, Inc. | Antibody-ALK5 inhibitor conjugates and their uses |
| EP3411404B1 (en) | 2016-02-03 | 2022-11-09 | Amgen Research (Munich) GmbH | Psma and cd3 bispecific t cell engaging antibody constructs |
| MY194596A (en) | 2016-09-23 | 2022-12-06 | Regeneron Pharma | Bi Specific Anti-Muc16-CD3 Antibodies And Anti-Muc16 Drug Conjugates |
| EP3548515B1 (en) | 2016-12-01 | 2026-01-21 | Regeneron Pharmaceuticals, Inc. | Radiolabeled anti-pd-l1 antibodies for immuno-pet imaging |
| CA3053348A1 (en) * | 2017-02-10 | 2018-08-16 | Regeneron Pharmaceuticals, Inc. | Radiolabeled anti-lag3 antibodies for immuno-pet imaging |
| RU2747095C2 (ru) * | 2018-05-11 | 2021-04-26 | Федеральное государственное бюджетное учреждение "Российский научный центр рентгенорадиологии" Министерства здравоохранения российской федерации (ФГБУ "РНЦРР" Минздрава России) | Мономолекулярный химерный т-клеточный рецептор к раковому антигену са125 |
| CN108659131B (zh) * | 2018-05-28 | 2021-09-14 | 长春力太生物技术有限公司 | 一种抗ceacam-5的单域抗体及其应用 |
| TW202504917A (zh) | 2018-06-21 | 2025-02-01 | 美商再生元醫藥公司 | 用雙特異性抗CD3xMUC16抗體及抗PD-1抗體治療癌症之方法 |
| WO2019246514A1 (en) | 2018-06-21 | 2019-12-26 | Regeneron Pharmaceuticals, Inc. | Bispecific anti-psma x anti-cd28 antibodies and uses thereof |
| TWI838389B (zh) | 2018-07-19 | 2024-04-11 | 美商再生元醫藥公司 | 雙特異性抗-BCMAｘ抗-CD3抗體及其用途 |
| MD4324851T2 (ro) | 2018-07-19 | 2025-12-31 | Regeneron Pharma | Receptori antigenici chimerici cu specificitate BCMA și utilizările acestora |
| EP3840841A1 (en) * | 2018-08-23 | 2021-06-30 | Regeneron Pharmaceuticals, Inc. | Anti-fc epsilon-r1 alpha (fcer1a) antibodies, bispecific antigen-binding molecules that bind fcer1a and cd3, and uses thereof |
| RS66543B1 (sr) | 2018-08-31 | 2025-03-31 | Regeneron Pharma | Strategija doziranja koja ublažava sindrom oslobađanja citokina za cd3/cd20 bispecifična antitela |
| ES2962578T3 (es) | 2018-10-31 | 2024-03-19 | Regeneron Pharma | Método y sistema de identificación y cuantificación de una proteína |
| MX2021005751A (es) * | 2018-11-16 | 2021-10-01 | Memorial Sloan Kettering Cancer Center | Anticuerpos contra mucina 16 y métodos de uso de los mismos. |
| US11249089B2 (en) | 2018-12-12 | 2022-02-15 | Regeneron Pharmaceuticals, Inc. | System and method of analysis of a protein using liquid chromatography-mass spectrometry |
| US11453721B2 (en) | 2018-12-19 | 2022-09-27 | Regeneran Pharmaceuticals, Inc. | Bispecific anti-MUC16 x anti-CD28 antibodies and uses thereof |
| MA54540A (fr) | 2018-12-19 | 2021-10-27 | Regeneron Pharma | Anticorps anti-cd28 x anti-cd22 bispécifiques et leurs utilisations |
| EA202192422A1 (ru) | 2019-03-05 | 2021-12-09 | Ридженерон Фармасьютикалз, Инк. | Человеческий сывороточный альбумин в составах |
| WO2020198009A1 (en) | 2019-03-22 | 2020-10-01 | Regeneron Pharmaceuticals, Inc. | EGFR x CD28 MULTISPECIFIC ANTIBODIES |
| WO2020227538A1 (en) * | 2019-05-08 | 2020-11-12 | Memorial Sloan Kettering Cancer Center | Humanized antibodies to mucin-16 and methods of use thereof |
| WO2020256721A1 (en) * | 2019-06-19 | 2020-12-24 | Synthis, Llc | Antib0dy-alk5 inhibitor conjugates and their uses |
| IL288916B2 (en) | 2019-06-21 | 2026-03-01 | Regeneron Pharma | Use of bispecific antigen-binding molecules that bind MUC16 and CD3 in combination with 4-1BB co-stimulation |
| EP3997124A4 (en) * | 2019-07-09 | 2024-01-03 | National Institute for Biotechnology in the Negev Ltd. | ANTIBODIES WITH REDUCED IMMUNOGENICITY |
| CN114302893B (zh) * | 2019-08-15 | 2025-01-28 | 瑞泽恩制药公司 | 用于细胞靶向的多特异性抗原结合分子及其用途 |
| CN112969715B (zh) * | 2019-08-21 | 2022-03-18 | 和铂医药(上海)有限责任公司 | 一种抗cd47抗原结合蛋白及其应用 |
| US11634500B2 (en) * | 2019-09-06 | 2023-04-25 | Les Laboratoires Servier | Anti-CD73 antibodies and compositions |
| US11896682B2 (en) | 2019-09-16 | 2024-02-13 | Regeneron Pharmaceuticals, Inc. | Radiolabeled MET binding proteins for immuno-PET imaging and methods of use thereof |
| US11814428B2 (en) * | 2019-09-19 | 2023-11-14 | Regeneron Pharmaceuticals, Inc. | Anti-PTCRA antibody-drug conjugates and uses thereof |
| WO2021113701A1 (en) * | 2019-12-06 | 2021-06-10 | Regeneron Pharmaceuticals, Inc. | Methods of treating multiple myeloma with bispecific anti-bcma x anti-cd3 antibodies |
| US11180540B2 (en) | 2019-12-06 | 2021-11-23 | Regeneron Pharmaceuticals, Inc. | Anti-VEGF protein compositions and methods for producing the same |
| KR20210095781A (ko) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물 |
| JP2023525034A (ja) | 2020-05-08 | 2023-06-14 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｖｅｇｆトラップおよびミニトラップならびに眼障害およびがんの治療方法 |
| MX2023007357A (es) * | 2020-12-22 | 2023-07-03 | Amgen Inc | Ensayo de gradiente de difusion para moleculas que contienen anti-cd3. |
| FI4284512T3 (fi) | 2021-01-28 | 2025-05-22 | Regeneron Pharma | Koostumuksia ja menetelmiä sytokiinien vapautumisoireyhtymän hoitamiseksi |
| TW202304507A (zh) | 2021-04-02 | 2023-02-01 | 美商再生元醫藥公司 | 含有抗ｍｕｃ１６ｘ抗ｃｄ３雙特異性抗體之穩定調配物 |
| EP4355778A1 (en) | 2021-06-17 | 2024-04-24 | Boehringer Ingelheim International GmbH | Novel tri-specific binding molecules |
| EP4437003A1 (en) | 2021-11-24 | 2024-10-02 | Regeneron Pharmaceuticals, Inc. | Methods for treating cancer with bispecific anti-cd3 x muc16 antibodies and anti-ctla-4 antibodies |
| KR20240130137A (ko) | 2022-01-07 | 2024-08-28 | 리제너론 파아마슈티컬스, 인크. | 이중특이적 항-MUC16 x 항-CD3 항체 단독으로 또는 항-PD-1 항체와의 조합으로 재발성 난소암을 치료하는 방법 |
| CA3246886A1 (en) * | 2022-01-10 | 2023-07-13 | Regeneron Pharmaceuticals, Inc. | CHIMERIC ANTIGENIC RECEPTORS TARGETING MUC16 |
| US20250092135A1 (en) * | 2022-01-10 | 2025-03-20 | Nanjing Leads Biolabs Co., Ltd. | Antibody and use thereof |
| KR20240159849A (ko) | 2022-03-17 | 2024-11-06 | 리제너론 파아마슈티컬스, 인크. | 이중특이적 항-MUC16 x 항-CD3 항체 단독으로 또는 항-PD-1 항체와 병용으로 재발성 상피 육종을 치료하는 방법 |
| CN119546329A (zh) | 2022-04-11 | 2025-02-28 | 瑞泽恩制药公司 | 用于通用肿瘤细胞杀伤的组合物和方法 |
| EP4584300A1 (en) * | 2022-09-06 | 2025-07-16 | TJ Biopharma (Shanghai) Co., Ltd. | Multispecific constructs and uses thereof |
| US20250076310A1 (en) | 2022-12-08 | 2025-03-06 | Regeneron Pharmaceuticals, Inc. | Methods to characterizing a fragment crystallizable domain of a bispecific antibody |
| KR20250151441A (ko) | 2023-02-17 | 2025-10-21 | 리제너론 파마슈티칼스 인코포레이티드 | Cd3/taa 이중특이적 항체에 대해 반응성인 유도된 nk 세포 |
| TW202500582A (zh) | 2023-03-13 | 2025-01-01 | 美商再生元醫藥公司 | 以雙特異性抗cd22x抗cd28分子治療癌症之方法 |
| PE20260306A1 (es) | 2023-06-12 | 2026-02-11 | Amgen Inc | Proteinas de union a receptor de linfotoxina beta agonistas |
| AU2024287529A1 (en) | 2023-07-10 | 2026-02-05 | Regeneron Pharmaceuticals, Inc. | Bispecific pd-l1x4-1bb antibodies and methods of use thereof |
| CN121666403A (zh) | 2023-07-10 | 2026-03-13 | 瑞泽恩制药公司 | 双特异性PD-L1xCD28抗体及其使用方法 |
| WO2025036848A1 (en) | 2023-08-11 | 2025-02-20 | Wuxi Biologics (Shanghai) Co., Ltd. | Anti-muc16 antibodies and uses thereof |
| CN117024596B (zh) * | 2023-08-18 | 2024-02-27 | 镜像绮点(上海)细胞技术有限公司 | 肿瘤原代细胞特异性标记与活体成像 |
| US20250114469A1 (en) | 2023-10-09 | 2025-04-10 | Regeneron Pharmaceuticals, Inc. | METHODS OF TREATING CANCER WITH A COMBINATION OF A TAAxCD3 BISPECIFIC ANTIBODY AND A TARGETED IMMUNOCYTOKINE |
| CN119978126A (zh) * | 2023-11-10 | 2025-05-13 | 深圳市菲鹏生物治疗股份有限公司 | 抗muc16抗体、靶向muc16的嵌合抗原受体及其应用 |
| TW202523694A (zh) * | 2023-11-17 | 2025-06-16 | 中國大陸商上海藥明生物技術有限公司 | 抗muc16抗體及其用途 |
| TW202539732A (zh) | 2023-11-29 | 2025-10-16 | 美商再生元醫藥公司 | 以雙特異性抗muc16×抗cd28抗體與抗pd-1抗體之組合或與雙特異性抗muc16×抗cd3抗體之組合治療復發性卵巢癌及子宮內膜癌之方法 |
| TW202542187A (zh) | 2023-12-12 | 2025-11-01 | 美商再生元醫藥公司 | 以雙特異性抗muc16x抗cd3抗體單獨或與抗pd-1抗體組合治療子宮內膜癌之方法 |
| WO2026015612A1 (en) | 2024-07-10 | 2026-01-15 | Regeneron Pharmaceuticals, Inc. | Methods of treating smarcb1-deficient cancers |
| WO2026050255A2 (en) | 2024-08-27 | 2026-03-05 | Regeneron Pharmaceuticals, Inc. | Anti-slc3a2-apis antigen-binding proteins and methods of use thereof |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| US20070258987A1 (en) | 2000-11-28 | 2007-11-08 | Seattle Genetics, Inc. | Recombinant Anti-Cd30 Antibodies and Uses Thereof |
| MXPA03009510A (es) * | 2001-04-17 | 2005-04-29 | Univ Arkansas | Secuencias de repeticion del gen ca125 y su uso para intervenciones de diagnosticos y terapeuticas. |
| EP1318402B1 (de) | 2001-12-04 | 2005-04-20 | B.R.A.H.M.S Aktiengesellschaft | Verfahren zur Diagnose von Sepsis unter Bestimmung von CA 125 |
| SI2301965T1 (sl) | 2002-10-16 | 2015-07-31 | Purdue Pharma L.P. | Protitelesa, ki vežejo celično- povezan CA 125 / O722P in metode uporabe le-teh |
| SI1629011T1 (sl) | 2003-05-31 | 2010-05-31 | Micromet Ag | Humane molekule za vezavo anti hu cd |
| EP1718667B1 (en) | 2004-02-23 | 2013-01-09 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
| AR048098A1 (es) | 2004-03-15 | 2006-03-29 | Wyeth Corp | Conjugados de caliqueamicina |
| US7750116B1 (en) | 2006-02-18 | 2010-07-06 | Seattle Genetics, Inc. | Antibody drug conjugate metabolites |
| ES2398076T3 (es) | 2006-06-02 | 2013-03-13 | Regeneron Pharmaceuticals, Inc. | Anticuerpos de alta afinidad contra el receptor de IL-6 humano |
| NO347649B1 (no) | 2006-12-14 | 2024-02-12 | Regeneron Pharma | Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse. |
| WO2008122039A2 (en) | 2007-04-02 | 2008-10-09 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Selenocysteine mediated hybrid antibody molecules |
| EP2144628B1 (en) | 2007-05-08 | 2012-10-17 | Genentech, Inc. | Cysteine engineered anti-muc16 antibodies and antibody drug conjugates |
| JP2010528285A (ja) | 2007-05-23 | 2010-08-19 | ベンタナ・メデイカル・システムズ・インコーポレーテツド | 免疫組織化学およびｉｎｓｉｔｕハイブリダーゼーションのためのポリマー担体 |
| US8187801B2 (en) | 2008-04-24 | 2012-05-29 | Wisconsin Alumni Research Foundation | Methods and kits to detect and monitor ovarian cancer and preeclampsia |
| EP2276506A4 (en) | 2008-04-30 | 2014-05-07 | Immunogen Inc | EFFICIENT CONJUGATES AND HYDROPHILIC BINDER |
| EP2374481B1 (en) | 2008-07-21 | 2015-11-04 | Polytherics Limited | Novel reagents and method for conjugating biological molecules |
| JP5816170B2 (ja) | 2009-06-26 | 2015-11-18 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体 |
| JO3182B1 (ar) | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
| JP5954789B2 (ja) | 2009-08-10 | 2016-07-20 | ユーシーエル ビジネス パブリック リミテッド カンパニー | 機能的分子の可逆的共有結合 |
| SI2501817T2 (sl) | 2010-02-08 | 2021-09-30 | Regeneron Pharmaceuticals, Inc. | Miš z navadno lahko verigo |
| PT2552959T (pt) | 2010-03-26 | 2017-04-21 | Memorial Sloan Kettering Cancer Center | Anticorpos para muc16 e métodos de utilização dos mesmos |
| DK2528625T3 (da) | 2010-04-15 | 2013-10-14 | Spirogen Sarl | Pyrrolobenzodiazepiner og konjugater deraf |
| US20130244905A1 (en) | 2010-07-06 | 2013-09-19 | Ed Grabczyk | Reporter for RNA Polymerase II Termination |
| US9220773B2 (en) * | 2010-11-26 | 2015-12-29 | University Of The Witwatersrand, Johannesburg | Pharmaceutical composition |
| KR20140037105A (ko) | 2011-05-27 | 2014-03-26 | 암브룩스, 인코포레이티드 | 비-천연 아미노산 연결된 돌라스타틴 유도체를 함유하는 조성물, 이를 수반하는 방법, 및 용도 |
| US8815226B2 (en) | 2011-06-10 | 2014-08-26 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
| WO2013055993A1 (en) | 2011-10-14 | 2013-04-18 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
| CA2850103C (en) | 2011-10-14 | 2019-09-10 | Spirogen Sarl | Pyrrolobenzodiazepines |
| CA2850096C (en) | 2011-10-14 | 2018-07-03 | Spirogen Sarl | Synthesis method and intermediates useful in the preparation of pyrrolobenzodiazepines |
| ES2945932T3 (es) | 2011-10-14 | 2023-07-10 | Seagen Inc | Pirrolobenzodiazepinas y conjugados dirigidos |
| WO2013068874A1 (en) | 2011-11-11 | 2013-05-16 | Pfizer Inc. | Antibody-drug conjugates |
| CN104244718A (zh) | 2011-12-05 | 2014-12-24 | 伊格尼卡生物治疗公司 | 抗体-药物缀合物以及相关化合物、组合物和方法 |
| JOP20200236A1 (ar) * | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| TWI682941B (zh) | 2013-02-01 | 2020-01-21 | 美商再生元醫藥公司 | 含嵌合恆定區之抗體 |
| MX379256B (es) | 2013-03-15 | 2025-03-10 | Regeneron Pharma | Moleculas biologicamente activas, conjugados de las mismas, y usos terapeuticos. |
| KR102252925B1 (ko) | 2013-08-26 | 2021-05-18 | 리제너론 파마슈티칼스 인코포레이티드 | 마크롤라이드 디아스테레오머를 포함하는 약제학적 조성물, 이의 합성 방법 및 치료학적 용도 |
| UA129760C2 (uk) * | 2013-12-17 | 2025-07-30 | Дженентек, Інк. | Анти-cd3 антитіло та спосіб його застосування |
| TWI754319B (zh) * | 2014-03-19 | 2022-02-01 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| EA201790719A1 (ru) * | 2014-09-26 | 2017-07-31 | Макродженикс, Инк. | Биспецифические моновалентные диатела, которые способны связывать cd19 и cd3, а также их применения |
| CN107667120B (zh) * | 2015-03-17 | 2022-03-08 | 纪念斯隆-凯特林癌症中心 | 抗muc16抗体及其应用 |
| EA034950B1 (ru) | 2015-03-27 | 2020-04-09 | Регенерон Фармасьютикалз, Инк. | Производные майтанзиноида, их конъюгаты и способы использования |
| LT3353212T (lt) | 2015-09-23 | 2021-12-27 | Regeneron Pharmaceuticals, Inc. | Optimizuoti anti-cd3 bispecifiniai antikūnai ir jų naudojimas |
| MY194596A (en) | 2016-09-23 | 2022-12-06 | Regeneron Pharma | Bi Specific Anti-Muc16-CD3 Antibodies And Anti-Muc16 Drug Conjugates |
| IL288916B2 (en) * | 2019-06-21 | 2026-03-01 | Regeneron Pharma | Use of bispecific antigen-binding molecules that bind MUC16 and CD3 in combination with 4-1BB co-stimulation |
| TW202304507A (zh) * | 2021-04-02 | 2023-02-01 | 美商再生元醫藥公司 | 含有抗ｍｕｃ１６ｘ抗ｃｄ３雙特異性抗體之穩定調配物 |
| EP4437003A1 (en) * | 2021-11-24 | 2024-10-02 | Regeneron Pharmaceuticals, Inc. | Methods for treating cancer with bispecific anti-cd3 x muc16 antibodies and anti-ctla-4 antibodies |
| KR20240130137A (ko) * | 2022-01-07 | 2024-08-28 | 리제너론 파아마슈티컬스, 인크. | 이중특이적 항-MUC16 x 항-CD3 항체 단독으로 또는 항-PD-1 항체와의 조합으로 재발성 난소암을 치료하는 방법 |
-
2017
- 2017-09-22 MY MYPI2019001357A patent/MY194596A/en unknown
- 2017-09-22 KR KR1020197011419A patent/KR102418667B1/ko active Active
- 2017-09-22 ES ES17784089T patent/ES2952735T3/es active Active
- 2017-09-22 EP EP23182446.7A patent/EP4273172A3/en active Pending
- 2017-09-22 CN CN201780067123.9A patent/CN110214026B/zh active Active
- 2017-09-22 HU HUE17784089A patent/HUE063020T2/hu unknown
- 2017-09-22 AU AU2017339711A patent/AU2017339711B2/en active Active
- 2017-09-22 RS RS20220906A patent/RS63660B1/sr unknown
- 2017-09-22 EP EP17784089.9A patent/EP3515487B1/en active Active
- 2017-09-22 HU HUE17787989A patent/HUE059761T2/hu unknown
- 2017-09-22 PL PL17784089.9T patent/PL3515487T3/pl unknown
- 2017-09-22 SM SM20220359T patent/SMT202200359T1/it unknown
- 2017-09-22 AU AU2017331363A patent/AU2017331363B2/en active Active
- 2017-09-22 MY MYPI2019001374A patent/MY200230A/en unknown
- 2017-09-22 JP JP2019515905A patent/JP7066691B2/ja active Active
- 2017-09-22 MD MDE20190826T patent/MD3515487T2/ro unknown
- 2017-09-22 SI SI201731189T patent/SI3515946T1/sl unknown
- 2017-09-22 WO PCT/US2017/053113 patent/WO2018067331A1/en not_active Ceased
- 2017-09-22 US US15/713,574 patent/US10738130B2/en active Active
- 2017-09-22 KR KR1020197010783A patent/KR102531251B1/ko active Active
- 2017-09-22 WO PCT/US2017/053114 patent/WO2018058003A1/en not_active Ceased
- 2017-09-22 IL IL265369A patent/IL265369B2/en unknown
- 2017-09-22 EP EP17787989.7A patent/EP3515946B1/en active Active
- 2017-09-22 CA CA3037536A patent/CA3037536C/en active Active
- 2017-09-22 CN CN201780071820.1A patent/CN110036032B/zh active Active
- 2017-09-22 SM SM20230308T patent/SMT202300308T1/it unknown
- 2017-09-22 DK DK17787989.7T patent/DK3515946T5/da active
- 2017-09-22 CA CA3287248A patent/CA3287248A1/en active Pending
- 2017-09-22 MX MX2019003322A patent/MX2019003322A/es unknown
- 2017-09-22 ES ES17787989T patent/ES2925563T3/es active Active
- 2017-09-22 PL PL17787989.7T patent/PL3515946T3/pl unknown
- 2017-09-22 JP JP2019515904A patent/JP7066690B2/ja active Active
- 2017-09-22 HR HRP20221202TT patent/HRP20221202T1/hr unknown
- 2017-09-22 SI SI201731387T patent/SI3515487T1/sl unknown
- 2017-09-22 CA CA3037738A patent/CA3037738A1/en active Pending
- 2017-09-22 FI FIEP17784089.9T patent/FI3515487T3/fi active
- 2017-09-22 PT PT177840899T patent/PT3515487T/pt unknown
- 2017-09-22 MX MX2019003326A patent/MX2019003326A/es unknown
- 2017-09-22 LT LTEPPCT/US2017/053113T patent/LT3515487T/lt unknown
- 2017-09-22 HR HRP20231281TT patent/HRP20231281T1/hr unknown
- 2017-09-22 LT LTEPPCT/US2017/053114T patent/LT3515946T/lt unknown
- 2017-09-22 RS RS20230945A patent/RS64691B1/sr unknown
- 2017-09-22 BR BR112019005670-0A patent/BR112019005670A2/pt active Search and Examination
- 2017-09-22 PT PT177879897T patent/PT3515946T/pt unknown
- 2017-09-22 IL IL265309A patent/IL265309B2/en unknown
- 2017-09-22 DK DK17784089.9T patent/DK3515487T5/da active
- 2017-09-22 BR BR112019005697-1A patent/BR112019005697A2/pt unknown
- 2017-09-22 US US15/713,578 patent/US10941208B2/en active Active
-
2019
- 2019-03-13 ZA ZA2019/01557A patent/ZA201901557B/en unknown
- 2019-03-14 ZA ZA2019/01591A patent/ZA201901591B/en unknown
- 2019-03-14 PH PH12019500550A patent/PH12019500550A1/en unknown
- 2019-03-19 PH PH12019500604A patent/PH12019500604A1/en unknown
- 2019-03-19 CL CL2019000712A patent/CL2019000712A1/es unknown
- 2019-03-20 CL CL2019000726A patent/CL2019000726A1/es unknown
- 2019-04-22 CO CONC2019/0003967A patent/CO2019003967A2/es unknown
-
2020
- 2020-06-26 US US16/913,154 patent/US11485793B2/en active Active
-
2021
- 2021-10-08 CL CL2021002645A patent/CL2021002645A1/es unknown
-
2022
- 2022-09-26 US US17/953,114 patent/US12570764B2/en active Active
- 2022-09-27 CY CY20221100635T patent/CY1125577T1/el unknown
-
2023
- 2023-09-08 CL CL2023002690A patent/CL2023002690A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019533807A5 (https=) | ||
| US20250066472A1 (en) | Ror1 antibodies | |
| JP2016524592A5 (https=) | ||
| ES2469369T3 (es) | Anticuerpos anti-CXCR4 humanizados para el tratamiento del cáncer | |
| TW201945396A (zh) | 最佳化抗-tl1a抗體 | |
| JP2012529281A5 (https=) | ||
| JP2012012402A5 (https=) | ||
| US10772969B2 (en) | N-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto | |
| JP2014512812A5 (https=) | ||
| JP2013506428A5 (https=) | ||
| JP2015533788A5 (https=) | ||
| CN115066435A (zh) | 针对lilrb2的单域抗体 | |
| JP2022028790A (ja) | 腎疾患及び歯周疾患を検出及び診断するための方法及び組成物 | |
| JP7820532B2 (ja) | ネクチン細胞接着分子４に特異的な抗体及びその使用 | |
| WO2018199318A1 (ja) | 抗ｇｐｃ－１抗体 | |
| WO2009056342A1 (en) | Binding epitopes for g250 antibody | |
| JP2017538439A5 (https=) | ||
| AU2017335991A1 (en) | Neutralizing antibodies to the αVβ8 integrin complex for immunotherapy | |
| JP2014515600A5 (https=) | ||
| JP2014500862A5 (https=) | ||
| WO2017079834A1 (en) | Epitopes in amyloid beta and conformationally-selective antibodies thereto | |
| JP2025512827A (ja) | 抗体、融合タンパク質及びその使用 | |
| JP2024512260A (ja) | Ｖｅｇｆａ結合分子 | |
| JP2019508684A (ja) | 活動性結核の診断のための方法及びキット | |
| CA2618920A1 (en) | Human monoclonal antibodies that specifically bind igf-ii |